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Abstract 
Despite significant advances in diagnosis and treatment, the prognosis of esophageal adenocar-
cinoma remains poor highlighting the importance of early detection. Although white light (WL) 
upper endoscopy can be used for screening of the esophagus, it has limited sensitivity for early 
stage disease. Thus, development of new imaging technology to improve the diagnostic capabilities 
of upper GI endoscopy for early detection of esophageal adenocarcinoma is an important unmet 
need. The goal of this study was to develop a method for the detection of malignant lesions in the 
esophagus using WL upper endoscopy combined with near infrared (NIR) imaging with a protease 
activatable probe (Prosense750) selective for cathepsin B (CTSB). An orthotopic murine model 
for distal esophageal adenocarcinoma was generated through the implantation of OE-33 and 
OE-19 human esophageal adenocarcinoma lines in immunocompromised mice. The mice were 
imaged simultaneously for WL and NIR signal using a custom-built dual channel upper GI endo-
scope. The presence of tumor was confirmed by histology and target to background ratios (TBR) 
were compared for both WL and NIR imaging. NIR imaging with ProSense750 significantly im-
proved upon the TBRs of esophageal tumor foci, with a TBR of 3.64±0.14 and 4.50±0.11 for the 
OE-33 and OE-19 tumors respectively, compared to 0.88±0.04 and 0.81±0.02 TBR for WL im-
aging. The combination of protease probes with novel imaging devices has the potential to improve 
esophageal tumor detection by fluorescently highlighting neoplastic regions. 
Key words: Esophageal Adenocarcinoma; Cathepsin B; Prosense750; Near Infrared Imaging. 
Introduction 
The  recent  epidemiological  shift  of  esophageal 
cancer in western countries from squamous cell car-
cinoma towards adenocarcinoma, which arises from 
prolonged Barrett’s esophagus, is reflected in the in-
creased  incidence  of  distal  esophageal  adenocarci-
noma  [1].  In  recent  decades  esophageal  adenocarci-
noma  has  had  the  fastest  growing  incidence  rate 
compared to any other cancer [2]; during the last 40 
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years its incidence has increased 300% in the United 
States [3]. Despite current advances in diagnosis and 
treatment as well as our understanding of underlying 
mechanisms leading to Barrett’s esophagus and ade-
nocarcinoma,  the  prognosis  of  the  patients  remain 
poor with a 5-year survival of about 15% [4, 5]. Like 
many other malignancies, early detection can improve 
the  prognosis  in  these  patients.  However,  current 
modalities for the detection of high grade dysplasia or 
early stage cancer is challenging as the appearance of 
the tissue at these stages of the disease can be difficult 
to  differentiate  from  normal  mucosa  using  conven-
tional white light (WL) endoscopy. Moreover, random 
biopsies to identify dysplastic regions within macro-
scopically  normal  appearing  esophagus  can  miss 
early cancers due to the patchy nature of the dysplasia 
[6]. 
Near Infrared (NIR) optical imaging combined 
with  fluorescent  probes  has  been  applied  towards 
more sensitive detection of a range of cancers includ-
ing  colon,  endometrial,  breast,  lung  and  prostate 
cancer [7-13]. A class of optical imaging agents that 
are “smart”, NIR protease activatable agents become 
brightly fluorescent in areas of increased cathepsin B 
(CTSB)  expression  [8,  14].  The  agents  are  optically 
silent in their native state and markedly increase their 
fluorescent intensity after enzyme-mediated release of 
fluorochromes, resulting in signal amplification at the 
site of release. Therefore, they offer a high tumor to 
background ratio compared with nonspecific agents, 
due to their selective activation.  
CTSB is a cysteine protease that actively partici-
pates in the proteolytic degradation of the extracellu-
lar matrix. It is believed that CTSB plays a critical role 
in tumor progression, and shows an overexpression in 
certain  tumors  of  the  lung,  breast,  stomach,  colon, 
esophagus and prostate [15-17] as well as esophageal 
adenocarcinoma  [18].  In  the  current  study  we  have 
developed  an  orthotopic  murine  model  of  distal 
esophageal  adenocarcinoma.  We  hypothesized  that 
NIR endoscopy with protease activatable agents can 
be used as an adjunct to WL endoscopy for sensitive 
detection of tumor foci in our esophageal adenocar-
cinoma  model.  We  demonstrated  the  ability  of 
Prosense750  in  delineating  esophageal  tumor  foci 
with a high tumor to background ratio (TBR) using 
our  in-house  custom  made  dual-channel  (WL  and 
NIR) upper GI endoscope system. 
Methods 
NIR activatable probe 
The  imaging  probe  used  for  this  study  is  a 
commercially available protease-activatable NIR flu-
orescent probe, Prosense750 (Perkin-Elmer, Waltham, 
MA).  The  probe's  structure  consists  of  a  synthetic 
graft polymer composed of poly-L-lysine that is ste-
rically  protected  by  multiple  methoxypolyethylene 
glycol side chains. Conjugated onto this lysine back-
bone are multiple NIR fluorochromes whose fluores-
cence is quenched by their proximity to one another in 
a phenomenon similar to fluorescence resonance en-
ergy transfer. Following a cleavage event by proteases 
that degrade the lysine backbone, the fluorochromes 
are released and thus regain their fluorescent proper-
ties, increasing the NIR signal intensity. 
Cell culture 
Human esophageal adenocarcinoma cancer cell 
lines  OE-33  and  OE-19  (both  from  Sigma-Aldrich) 
were  grown  in  RPMI,  containing  L-glutamine 
(CellGro by Mediatech Inc., Manassas, VA). The me-
dia were supplemented with 10% fetal bovine serum 
(Atlanta biologicals, Lawrenceville, GA) and 1% Pen-
icillin Streptomycin (CellGro by Mediatech Inc.). Cells 
were maintained in a  humidified incubator at 37C 
and 5% CO2. 
 
Surgical procedure and tumor implantation 
OE-33 and OE-19 cells were grown in cell culture 
medium until they were ~90% confluent. Cells were 
trypsinized,  washed  three  times  with  PBS  and  col-
lected  by  centrifugation  (5min,  1200rpm,  RT).  Cells 
were diluted 25x106/mL in PBS and kept on ice until 
injection.  
Six to 8-week old female athymic Balb/C nude 
mice (3 groups, n=5 each) were obtained from Charles 
River  Laboratories  International  Inc.,  (Wilmington, 
MA). Mice were anesthetized by IP administration of 
ketamine  (100mg/kg)  and  xylazine(10mg/kg).  The 
surgical procedure was performed under a stereomi-
croscope (Nikon, Tokyo, Japan) with a 10:1 zoom ra-
tio.  After  induction  of  the  anesthesia,  the  anterior 
abdomen  wall  was  swabbed  with  povidone-iodine 
solution and a midline incision below the costal mar-
gin  was  made  to  access  the  abdominal  esophagus. 
Clean  sterilized  cotton  tips  were  carefully  used  to 
expose the distal esophagus. Pre-cell injection average 
esophageal wall thickness including the mucosa and 
submucosa in mouse was measured to be between 400 
and 500 microns. Approximately, 5x105 cells (group 
A= OE-33, group B= OE-19, and group C= PBS) were 
injected in 20 uL of PBS using a 32-gauge needle into 
the distal esophagus proximal to the gastroesophageal 
junction (Figure 1). Observation of a small bulge in the 
esophagus  wall  was  considered  as  the  sign  of  suc-
cessful implantation.  Theranostics 2012, 2(2) 
 
http://www.thno.org 
229 
 
Figure 1: Images acquired during the surgery to generate the orthotopic model of distal esophageal adenocarcinoma. Distal esophagus 
(panel A, white arrow) was exposed following a midline incision in the upper abdomen. The 32-guage needle was inserted into the 
esophagus wall (panel B, white arrow) and after injection, induction of a small bulge (panel C, white arrow) was considered as a sign of 
successful injection.  
 
After  careful  observation  of  the  animals  over 
several minutes to ensure that the cells did not leak 
from the injection site, the abdominal wall and skin 
were closed using 5-0 prolene sutures. The animals 
were  observed  until  recovered  from  anesthesia  and 
were  kept  for  4  weeks  under  standard  laboratory 
conditions  with  free  access  to  water  and  food  in  a 
12-hour light/dark schedule until tumors reached a 
size of 2-3 mm in diameter. Pain reduction precau-
tions were administered according to the institutional 
guidelines. 
Small Animal Upper GI endoscopy and ex vivo 
imaging 
The  animals  received  2nmol  of  Prosense750 
(Perkin-Elmer, Waltam, MA) via tail vein under 2% 
isoflurane anesthesia, 24 hours prior to the upper GI 
endoscopy.  For  the  endoscopy,  anesthesia  was  in-
duced using 5% isoflurane and 100% oxygen mixture 
and  the  animals  were  fixed  on  a  regulated  heating 
plate to maintain the body temperature at 37°C. The 
animals were then intubated using a 22-guage plastic 
catheter that was connected to a small animal respi-
rator  (Harvard  apparatus,  Holliston,  MA)  and  the 
anesthesia was maintained by 1% isoflurane.  
The upper endoscopy was performed using our 
in-house custom-made multichannel endoscopy sys-
tem (two channels for WL and NIR); the design of the 
endoscope  system  has  previously  described  by  our 
group [10]. The flexible imaging catheter was gently 
introduced  through  the  oropharynx  while  air  was 
insufflated through the endoscope working channel 
by a 10 ml syringe. Simultaneous WL and NIR images 
from  esophagus  were  acquired  with  slow  advance-
ment of the fiberscope.  
After endoscopy, the animals were immediately 
sacrificed using a CO2 chamber, the thorax and ab-
domen  were  opened  and  esophagi  were  dissected. 
Epifluorescence imaging was performed using an in 
vivo multispectral whole animal optical imaging sys-
tem (Carestream, Rochester, NY). A 750nm excitation 
filter and an 810 nm emission filter were used (excita-
tion and emission ranges for the Prosense750 probe) 
to image the signal generated from the activated NIR 
probe. To evaluate the fluorescent biodistribution of 
the  probe,  non-tumor  bearing  mice  were  also  dis-
sected and the organs were imaged on the same sys-
tem to find the baseline signal in the different organs 
including the esophagus and stomach, 24 hours after 
Prosense750 injection.  
Quantitative measurements were performed on 
the acquired near-infrared images. The mean signal 
intensity  and  standard  error  of  mean  of  esophagus 
tumor and an adjacent esophagus normal mucosa, as 
well as a region outside the specimen (noise), were 
measured on 12-bit gray-scale images using proprie-
tary software  [19]. The target (esophagus tumor) to 
background (normal esophagus) contrast (TBC) was 
calculated as follows: TBR % = (ET - Noise) / (NE - 
Noise) Where: ET = esophagus tumor, NE = normal 
esophagus.  The  mean  signal  intensity  in  re-
gions-of-interest (ROI) of constant size comprising 10 
x  10  units  of  width  and  height  was  measured.  The 
tumor bearing ROI were placed with the center over 
the  respective  brightest  fluorescence  in  the  tumors; 
the normal esophagus ROI (background) were placed 
over normal esophagus tissue at a distance of three 
region-of-interest  diameters  from  the  tumor  center; 
the  noise  was  measured  on  the  image  outside  the 
specimen.  For  consistency,  the  same  investigator 
placed  all  regions-of-interest.  The  data  is  shown  as 
mean±SEM. Signal intensity (SI) of esophagus tumor 
from  animals  injected  with  OE-33  and  OE-19  cells 
were  compared  with  signal  intensity  of  esophagus 
injection region from animals injected with PBS in the 
distal esophagus, using a two-tailed Student t test for Theranostics 2012, 2(2) 
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independent samples. A p value <0.05 was considered 
to be significant. 
Histological confirmation and Immunohisto-
chemistry  
The extracted esophagus samples were immedi-
ately transferred into formalin for fixation and further 
processing. The paraffin embedded blocks were pre-
pared and slices were cut and stained. Hematoxylin 
and eosin (H&E) staining was used for the confirma-
tion of tumor presence. Consecutive slices were used 
for  immunohistochemistry  using  a  CTSB  primary 
antibody. Briefly, for CTSB staining, antigen retrieval 
was performed, and deparaffinized tissue sections in 
antigen retrieval Citra Solution (Biogenex Laborato-
ries, San Ramon, CA) were treated with microwaves 
in a pressure cooker (5 min). Tissue sections were in-
cubated with 5% normal rabbit serum (Vector Labor-
atories,  Burlingame,  CA)  in  PBS  (30  min).  Primary 
antibody  against  CTSB  [Goat  polyclonal  anti-CTSB 
(S-12), 1:1250 dilution; Santa Cruz Biotechnology, Inc., 
Santa  Cruz,  CA]  was  applied,  and  the  slides  were 
maintained at room temperature for 15min, followed 
by goat secondary antibody (Vector Laboratories) (30 
min),  an  avidin–biotin  complex  conjugate  (Vector 
Laboratories) (30 min), diaminobenzidine (5 min) and 
counterstained with hematoxylin. After preparation, 
all slides were evaluated by a pathologist for confir-
mation.  
Results 
Surgical outcome and animal model 
The depth of needle penetration for cell implan-
tation was controlled under streomicroscope  visuali-
zation in order to produce sub mucosa small distal 
esophagus tumor nodules that mimicked early human 
esophagus adenocarcinoma. There were no complica-
tions or surgically related mortalities in any of the 15 
mice.  
Small Animal Upper GI endoscopy and ex vivo 
epifluorescence imaging 
Fiber-optic esophagoscopy was performed in all 
three groups of the study, 24 hours after Prosense750 
probe  injection.  No  major  complication,  including 
perforation, was observed secondary to the endosco-
py  procedure.  The  WL  images  provided  anatomic 
localization  and  visual  clues  for  real  time  imaging 
while  the  NIR  images  reported  upon  the  protease 
activity. 
 
Figure 2: WL, NIR and overlay images of 
catheter-based  upper  GI  endoscopy  from 
OE-33 (panel A, B and C), OE-19 (panel D, E 
and F) and control (panel G, H and I) groups. 
Upper GI endoscopy demonstrates signifi-
cant elevated NIR signal at the tumor foci 
while  in  the  control  animals  the  signal  is 
absent in this region. 
 
The  tumors  were  early  in 
growth and there was no major ob-
struction  of  the  lumen  at  the  time 
point  evaluated.  All  of  the  tumors 
were visible on the NIR channel in 
group  A  and  B  mice  (OE-33  and 
OE-19  tumor  bearing  mice),  while 
no NIR signal was detectable above 
background  in  the  PBS-injected 
group. Due to small size of the le-
sions in some cases, the WL channel 
could  not  provide  adequate  visual 
contrast for detection of the tumors 
while they were brightly visible on 
the NIR channel. Figure 2 shows a 
sample of the WL and NIR channels 
and  the  overlay  images  acquired 
from each group.  
Analysis  of  the  NIR  and  WL 
signal and the TBR demonstrated a Theranostics 2012, 2(2) 
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several fold increase in the NIR signal in the OE-33 
and OE-19 group in comparison to the controls. The 
NIR TBR in the OE-33 and OE-19 were 3.64±0.14 and 
4.50±0.11,  respectively,  which  were  significantly 
higher compared to the control group  non-elevated 
NIR  TBR  of  1.08±0.08  (p<0.0001).  The  WL  TBR 
(0.88±0.04 and 0.81±0.02 for OE-33 and OE-19 groups, 
respectively)  was  comparable  to  the  WL  TBR  of 
0.97±0.05 for the control group. Figure 3 shows results 
of this analysis for each group separately.  
 
 
Figure  3: TBR of NIR optical imaging using CTSB activatable 
probe compared to WL in different groups of the study. NIR 
imaging after probe administration improves the TBR in the tumor 
bearing mice up to 4 fold; The TBR remains close to 1 for both 
tumor and control groups.  
Ex vivo imaging 
Epifluorescence  images  demonstrated  a  bright 
fluorescent signal from the tumor site of the animals 
injected  with  the  Prosense750  probe  in  contrast  to 
adjacent mucosa. Figure 4 shows a sample of these 
images.  Unlike  samples  from  OE-33  and  OE-19 
groups,  the  esophagus  samples  from  the  control 
group  did  not  show  high  focal  fluorescence  signal. 
The  biodistribution  study  demonstrated  high  NIR 
signal in skin, liver and kidneys, 24 hours after probe 
injection but not in other organs such as esophagus, 
intestines or blood. Figure 5 shows a sample of our 
biodistribution results. 
Pathology 
Tumors developed at the site of direct implanta-
tion in 100% (10/10) of animals, and formed esopha-
gus  nodules  4  weeks  after  tumor  cell  implantation. 
The presence of the submocusal tumor was confirmed 
in all samples via pathology and H&E staining. Im-
munohistochemistry  confirmed  the  elevated  expres-
sion of CTSB in the tumor site but not in the controls 
or unaffected tissue. Figure 6 shows a sample of H&E 
and immunohistochemistry for both OE-33 and con-
trol group.  
 
 
 
 
 
 
Figure 4: Ex vivo imaging of the mouse esophagus after dual channel upper GI endoscopy. Panel A and B demonstrates high focal NIR 
probe activity in small nodules in the esophagus of OE-33 and OE-19 tumor bearing mice, respectively. In panel C, a control mouse 
esophagus is displayed with no detectable focal fluorescence signal.  Theranostics 2012, 2(2) 
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Figure 5: Imaging the fluorescent bio-distribution of the probe 24 hours after injection demonstrates high signal in skin, liver and kidneys 
but not in the alimentary tract.  
 
Figure 6: After upper GI endoscopy and ex vivo imaging, presence of tumor was confirmed by pathology. Panel A shows an H&E image 
from an control mouse receiving PBS injection and panel C image is acquired from a tumor bearing mouse with OE-33 cells. Consecutive 
slides were used for IHC, which confirmed high expression of CTSB in the tumors (panel D) but not the normal esophagus (panel B). The 
tumor is shown by black arrow. Theranostics 2012, 2(2) 
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Discussion 
Activatable  molecularly  targeted  fluorescent 
probes  combined  with  minimally  invasive  imaging 
systems  for  optical  evaluation  have  numerous  ad-
vantages over other methods for finding early disease. 
In  particular,  protease  imaging  selective  for  CTSB 
offers  the  improved  detection  of  cancer  and 
premalignant  lesions  by  targeting  an  enzyme  class 
widely present across most cancers and in particular 
adenocarcinoma of esophagus and Barrett’s esopha-
gus [18, 20]. Such imaging yields high target to back-
ground ratios that markedly improve detection and 
that can help localize pathology. Near infrared imag-
ing allows simultaneous full color spectrum WL im-
aging  along  with  molecular  reporting  in  the  NIR, 
thereby providing anatomic landmarks and allowing 
the utilization of traditional anatomic cues for disease 
detection in addition to the fluorescent molecular re-
porters.  
Surface weighted optical techniques such as en-
doscopy result in sufficient tissue NIR photon pene-
tration to report on molecular targets up to 1 cm from 
the imaging surface. However, the pathology endo-
scopic systems are typically designed to detect is at 
the mucosal surface or within several mm of the sur-
face, so this degree of light penetration is within the 
requirements of such an approach. The imaging sys-
tems are readily combined with traditional WL optical 
devices, similar to the approach demonstrated in this 
study, allowing rapid implementation to patient care 
paradigms. Many of these systems have incorporated 
minimally  invasive  resection  capabilities,  providing 
an  option  for  therapeutic  intervention  immediately 
following  NIR  lesion  detection.  Finally,  the  lack  of 
ionizing  radiation  increases  the  potential  utilization 
for disease screening. 
In  this  study,  we  performed  a  comparison  be-
tween  conventional  WL  upper  endoscopy  and  NIR 
imaging with a protease sensitive imaging probe for 
esophageal  adenocarcinoma  foci  identification,  con-
firmed  with  histological  validation.  To  our 
knowledge, this is the first example of dual channel 
murine upper GI endoscopy. We also demonstrated 
for the first time a novel surgical approach to implant 
esophageal tumors orthotopically. Our results for two 
human esophageal adenocarcinomas showed an ap-
proximate  3.5--4.5-fold  tumor  to  background  ratio, 
demonstrating a beacon effect that could be used to 
highlight the location of small neoplastic foci in the 
esophagus. Low uptake and lack of activation of the 
CTSB selective probe in the adjacent normal esopha-
gus resulted in a relatively uniform low background, 
further  improved  lesion  conspicuity.  While  formal 
human  toxicology  studies  are  needed  for  human 
translation, we have not seen any preclinical toxicity 
using the imaging probe Prosense 750 at the reported 
doses.  Imaging  using  a  near  infrared  protease  acti-
vatable probe for esophageal adenocarcinoma in mice 
demonstrates a potential translatable path forward to 
improve  endoscopic  detection  of  early  esophageal 
cancers in patients in the future. 
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